Affymax, Inc. Reports Phase 2 Sub-Analysis of Hematide(TM) in Hemodialysis Patients

NASHVILLE, Tenn.--(BUSINESS WIRE)--Affymax, Inc. (Nasdaq:AFFY) today announced data from a post hoc sub-analysis of the Phase 2 clinical trial evaluation of Hematide in chronic renal failure patients undergoing dialysis. These data suggest that Hematide maintains stable hemoglobin levels in hemodialysis patients for up to two years regardless of baseline iron (ferritin and transferrin saturation [TSAT]) or C-reactive protein (CRP) status, key factors in anemia of chronic kidney disease that often impact responsiveness to therapy with erythropoiesis stimulating agents (ESAs).